Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Alirocumab on Reverse Cholesterol Transport
NCT03014830Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Jun 2017
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hypercholesterolemia comparing Alirocumab with Placebo (2 arms). Primary endpoints: Change from baseline in percent cholesterol excretion per day and Change from baseline in removal rate of esterified cholesterol from plasma per day. Started Jun 2017; status: completed.
02
Drugs
alirocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT03014830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03014830.